SelectImmune Pharma Collaborates with Lonza to Develop an Immunotherapeutic Drug Candidate
· The agreement provides access to vector construction and non-GMP expression of a novel immunotherapy protein drug candidate · Access to early material for pre-clinical testing will provide input for manufacturing process development necessary as the drug progresses towards clinical testingLund, Sweden and Basel, Switzerland, 21 June 2021 - SelectImmune Pharma, a pharmaceutical company developing novel immunotherapeutics and alternatives to antibiotics, and Lonza, a global CDMO partner to the biotech and biopharma industry, have announced today a collaboration to develop processes for